Abstract
Nipro Corporation, based in Osaka, Japan, is engaged in the manufacture and
marketing of medical devices, pharmaceuticals, glass and materials. The
company also operated supermarkets and consumer drug stores in Japan through
its Supermarket division, but sold these operations in June 2006.
The company' s core medical device activities, including dialysis devices,
insulin needles, lancets, infusion, blood glucose monitoring and circulatory
system products, are undertaken by its Medical division, which is Nipro' s
largest unit, accounting for 44% of the company' s total revenue in fiscal
2005. In addition, its Pharmaceutical division represented 17% of total sales
and offers and pre-filled injection and container systems, in addition to
pharmaceuticals such as dialysate products, lower dose drugs and infusion
drugs which are not covered by this profile.
The Medical division is also due to be expanded through Nipro' s August 2006
agreement to purchase Edwards Lifesciences' remaining perfusion products
business. Under terms of the agreement, Nipro Medical Ltda, Nipro' s subsidiary
in Sao Paulo, Brazil, will acquire Edwards' perfusion products business, which
is also based in Sao Paulo. Its products are sold throughout Latin America,
Asia, Eastern Europe and parts of the Middle East and Africa. Approximately
140 Edwards employees who work in the perfusion products operations are
expected to transfer to Nipro.
In Japan, Nipro owns two main research centres and three factories. The
company also operates at 37 locations, with four major manufacturing bases and
34 sales locations. In recent years, Nipro expanded the production capacities
of its international manufacturing facilities in order to reduce costs and
compete more successfully in the international market, and has also enhanced
its global presence with the expansion of sales activities in Europe, the
Americas and Asia.
Nipro' s total number of employees at 31st March 2006 increased by 431 compared
with the previous year to 9,048. The number of staff in Japan increased by 418
to 4,612 and the number in other countries rose by 13 to 4,436.
This company report provides
Executive Summary
An overview of the company, including operating activities, at a glance key
events and strategic focus.
Product Portfolio and R&D
The product section of the report focuses on the key aspects of the company' s
portfolio and technology, covering core products, key brands, new products and
analysis of the competition. Sales data, market size and future potential is
included where available.
International Activities
The company' s business activities by geographic region and country.
Appendices
- Financial Indicators
- Key corporate events
- Mergers & acquisitions
- Joint ventures
- Minority investments
- Divestitures
- Agreements
View Cart
